Skip to main content

Russia to supply Avifavir drug to 17 nations for Coronavirus Treatment

By Unknown

The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group have agreed to supply Avifavir, the world's first registered favipiravir-based drug against coronavirus and Russia’s first drug approved for the treatment of COVID-19, to 17 countries.

Avifavir and other favipiravir-based drugs produced in Russia, as well as Remdesivir developed in the US are currently the leading drugs against COVID-19registered globally.

Avifavir will be delivered to Argentina, Bulgaria, Brazil, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Saudi Arabia, Serbia, Slovakia,South Africa, UAE and Uruguay.

The drug has already been delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan.

On May 29, 2020, Avifavir received a registration certificate from Russia’s Ministry of Health based on thorough and transparent clinical data and became the first favipiravir-based drug in the world approved for the treatment of COVID-19. Approximately five months after the clinical trials of Avifavir in Russia, the efficacy of favipiravir against the novel coronavirus infection was confirmed by Japan’s Fujifilm. On September 23, 2020, the company announced that according to the results of its Phase III clinical trial, the administration of its favipiravir-based drug Avigan to 156 patients demonstrated shorter time to resolution as compared with the placebo group.

The efficacy of Avifavir has been demonstrated in clinical trials which significantly exceed in scale those conducted by other Russian manufacturers of favipiravir. These trials have been conducted in full compliance with international standards and the requirements of regulatory authorities around the world. Since April, 408patients with confirmed coronavirus have participated in the studies at 35 medical centers across Russia. In October the number of patients will increase to 460.

Since June 2020, more than 60,000 packages of Avifavir have been delivered to clinics in 74 Russian regions. Since the start of Avifavir supplies, clinical monitoring has been carried out based on data from the register of patients with coronavirus of the Ministry of Health of Russia. Data on the use of Avifavir has been collected, with further analysis as well as scientific and medical assessmentconducted. According to the results of the observational post-registration clinical trial of 940 patients, those taking Avifavir demonstrated elimination of the virus at an earlier stage in 30% of the cases and the level of oxygen saturation was restored to normal twice as quickly compared with standard therapy (within two days versus four days). According to the results of the research, the drug is well tolerated, with no new adverse events identified.

Avifavir is now the leading Russian anti-COVID drug in terms of exports. In particular, the start of deliveries to Bolivia and other countries in Latin America was announced on September 21 as part of the agreement to deliver 150,000 packs. Avifavir has also been approved by regulators in Europe, Middle East and Asia.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, “When we registered the first anti-coronavirus drug in the world based on favipiravir there was a lot of skepticism as people were wondering how we could register it when Japan had not registered it yet. Now five months after our clinical trials we see that Japan has confirmed the clinical efficacy of favipiravir. Avifavirhas been tested in more than 1,300 patients including 408 patients in clinical trials and 940 patients during the observational post-registration clinical trial.”

“We havenow conducted the largest clinical trial of a favipiravir-based drug against coronavirus in the world and can confirm its high efficacy. Since June, more than 60,000 packages of Avifavir have been delivered to clinics in 74 Russian regionsandnd more than 15 countries have confirmed their interest in the drug. Based on our extensive clinical trials and the research in Japan confirming favipiravir’sefficacy against coronavirus we believe that Avifavir and other favipiravir-based products will be the leading antiviral medicines against COVID-19 in the world. In addition to proven efficacy and safety Avifavir is also three to four times cheaper than Remdesivir."

RDIF is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn.

ChemRar Group unites R&D service and investment companies in the field of innovative pharmaceuticals for the development and commercialization of innovative medicines, diagnostics, preventive care and new treatments of life-threatening diseases in Russia and abroad


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more

Context & pre-existing barriers to education for girls and women

By Unknown
Education is a right for all children and an educated population is essential for building a self-reliant, peaceful, equal, and inclusive Afghan society. Afghanistan’s education system has been severely impacted by decades of conflict, widespread poverty and humanitarian crisis.  Today, funding remains insufficient, as only 3% of Afghanistan’s Gross Domestic Product is allocated to education. International standards state that the government should spend at least 4 to 6% of GDP on education.  The Incheon Declaration and Framework for Action for the implementation of Sustainable Development Goal 4 recognizes that to “ensure inclusive and equitable quality education and promote lifelong learning opportunities for all”, least developed countries need to dedicate at least or more than 4 to 6%.  Afghanistan budgets far less than this, and even with this small percentage of funding the country’s education budget continues to be underspent every year.Afghanistan has one of the y...
Post a Comment
Read more